Hormonal
SGLT-2 inhibitors provide cardiovascular and renal protective benefits independent of their glucose-lowering effects, including reduced risk of heart failure hospitalization and worsening renal function.
SGLT-2 inhibitors (like Jardiance or Farxiga) are not just for blood sugar. They are now a standard treatment for heart failure and kidney disease, even in people without diabetes. They significantly reduce the risk of being hospitalized for heart failure and slow down kidney damage. If you have heart or kidney issues, ask your doctor if this class of medication is appropriate for you.
High-certainty evidence suggests that SGLT-2i treatment decreases the risk of hospitalization due to HF, and moderately certain evidence may support that SGLT-2i reduces the incidence of worsening renal function
Why this rating
Supported by high-certainty evidence from large RCTs (EMPA-REG, DAPA-HF, etc.).
Source
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Xiayun Ni et al. · Frontiers in Pharmacology · 2022
DOI 10.3389/fphar.2022.877797
More from this paper
- Early combination therapy with new hypoglycemic drugs (SGLT-2i, GLP-1RA, or DPP-4i) achieves glycemic control faster and provides longer-lasting benefits compared to traditional stepwise monotherapy in prediabetes and type 2 diabetes.Good
- GLP-1 receptor agonists provide significant cardiovascular benefits, including reduced risk of major adverse cardiovascular events (MACE) and stroke, in addition to weight loss and glycemic control.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →